Pharmacokinetics and Toxicokinetics in Drug Development
Pharmacokinetics (PK) and toxicokinetics (TK) are critical components of drug development, focusing on the absorption, distribution, metabolism, and excretion (ADME) of compounds and their toxicological profiles. PK characterizes how a drug moves through the body, while TK evaluates the relationship between exposure and toxic effects.
In preclinical studies, PK/TK analyses help determine dosing regimens, bioavailability, and clearance rates. They provide quantitative data on systemic and tissue-specific drug concentrations over time, essential for interpreting efficacy and toxicity results.
Toxicokinetic studies often accompany repeated-dose toxicity assessments, correlating internal exposure to observed adverse effects. This information is pivotal for establishing safety margins and no-observed-adverse-effect levels (NOAELs).
Analytical techniques such as liquid chromatography-mass spectrometry (LC-MS) enable sensitive and specific measurement of drugs and metabolites in biological matrices. Modeling approaches integrate PK/TK data to predict human pharmacokinetics and guide clinical dosing.
Understanding PK and TK profiles supports risk assessment, regulatory submissions, and optimization of drug candidates, ultimately improving therapeutic outcomes and patient safety.